GE Achieves Record Transmission of Power on a Super Energy Highway in India
14.11.2019 14:59:00 EET | Business Wire | Press release
GE’s Grid Solutions business (NYSE:GE) announced today a new milestone in its Champa-Kurukshetra ultra-high-voltage direct current (UHVDC) project in India with the 1,305-km link now capable of transmitting 4,500 MW of electricity. This follows the recent successful energization of the third of four poles planned for the ±800kV UHVDC transmission line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005360/en/
Inside the Valve Hall of the Champa-Kurukshetra HVDC Converter Station, image courtesy of GE (Photo: Business Wire)
A special feature of the Champa project is the use of an overhead line with dedicated metallic return, which uses a neutral conductor as a part of the DC circuit. GE is the first company in the world to demonstrate this technology with this project and is therefore providing additional value to the customer by eliminating the typical technical and environmental issues associated with the traditional electrode solution.
The transmission line is a crucial component of the Indian government’s electricity-for-all initiative and will help provide reliable electricity for millions of people living in the states of Punjab, Haryana, Delhi, Uttar Pradesh and surrounding areas. The project is being executed by GE T&D India Limited, the listed entity of GE’s Grid Solutions business in India.
New government initiatives and robust private-sector investments have reversed India’s longstanding power deficit. With the growing renewable energy market, the nation now boasts an installed capacity of over 360 gigawatts (GW), making it the third-largest electricity producer in the world. However, to meet the government’s vision of power-to-all and to ensure last mile connectivity, continuous development of a robust transmission network is vital for the country.
Power Grid Corporation of India Ltd (POWERGRID), India’s largest state-owned transmission company, is helping address this issue by connecting the power deficit northern Indian region with power surplus regions of eastern India using GE’s UHVDC technology.
“Thanks to this latest milestone in the GE Champa-Kurukshetra project, India is now transmitting more electricity over this link than any other DC link in India, helping to resolve the supply shortfalls in the north. This project also includes an integration where two separately designed bi-poles are running in parallel operation over the same DC transmission line, a design feature only seen on two other HVDC projects in the world, both of which GE was involved with, a great compliment to our legacy and current HVDC controls capability. On behalf of everyone at GE’s Grid Solutions, I would like to thank our teams in India and our UK HVDC center of excellence for this remarkable feat,” said Rajendra Iyer, head of Grid Integrated Solutions at GE’s Grid Solutions. The Grid Integration Solutions division, comprised of High Voltage Direct Current (HVDC) and FACTS technologies, designs and integrates transmission solutions that help meet the world’s ever-evolving power needs.
The Champa-Kurukshetra project transmits electricity from power generating plants located across Chhattisgarh, a state in eastern region of India, to a GE-built rectifier station in Champa, where it is converted from alternating current (AC) to direct current (DC). The electricity is transported in bulk across the UHVDC line and is then converted back to AC by a GE inverter station in Kurukshetra, Haryana. From there, power is transported to the surrounding rural states who are in need of reliable and consistent electrical power. DC technology efficiently moves electricity over long distances which lowers transmission costs and losses. Additionally, it is a more environment-friendly technology because it requires fewer overhead lines to deliver the same amount of power as a high-voltage AC system.
Phase 1 of the project, completed in 2017, provided 3,000 MW of transmission capacity. GE’s recent energization of Pole 3 added another 1,500 MW of transmission capacity, marking a key benchmark towards the completion of Phase 2. Once Pole 4 is commissioned, the entire system will transmit 6,000 MW of electricity at 800kV - making the project one of the largest generation-to-consumption transmission systems in the world.
Notes to Editors:
About GE T&D India Limited:
GE T&D is the listed entity of GE’s Grid Solutions business in India. With over 100 years of presence in India, GE T&D India is a leading player in the Power Transmission & Distribution business with a product portfolio ranging from Medium Voltage to Ultra High Voltage (1,200 kilovolt) for Power Generation, Transmission and Distribution, Industry and Infrastructure markets.
GE T&D India has a significant presence in all stages of the power supply chain and offers a wide range of products that include Power Transformers, Circuit Breakers, Gas Insulated Switchgears, Instrument Transformers, Substation Automation Equipment. Digital Software Solutions, Turnkey Solutions for Substation Engineering & Construction, Flexible AC Transmission Systems, High Voltage DC & Services suite of offerings. With six manufacturing sites, GE T&D India is future ready to meet the growing demands for equipment and services. GE is focused towards on introducing Green and Digital Solutions aimed towards making the Indian Grid smarter and more environmentally-friendly.
About GE’s Grid Solutions:
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. For more about GE Renewable Energy’s Grid Solutions business, visit www.gegridsolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005360/en/
Contact information
For media queries, please contact:
Anshul Madaan
Communications Leader
GE Grid Solutions – South Asia
anshul.madaan@ge.com
Allison J. Cohen
GE Renewable Energy, Grid Solutions business
External Communications Manager
+972-(0)54-7299742
allison.j.cohen@ge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom